1
|
Arancibia T, Morales-Pison S, Maldonado E, Jara L. Association between single-nucleotide polymorphisms in miRNA and breast cancer risk: an updated review. Biol Res 2021; 54:26. [PMID: 34454612 PMCID: PMC8401249 DOI: 10.1186/s40659-021-00349-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Accepted: 08/13/2021] [Indexed: 12/27/2022] Open
Abstract
Breast cancer (BC), a heterogeneous, aggressive illness with high mortality, is essentially a genomic disease. While the high-penetrance genes BRCA1 and BRCA2 play important roles in tumorigenesis, moderate- and low-penetrance genes are also involved. Single-nucleotide polymorphisms (SNPs) in microRNA (miRNA) genes have recently been identified as BC risk factors. miRNA genes are currently classified as low-penetrance. SNPs are the most common variations in the human genome. While the role of miRNA SNPs in BC susceptibility has been studied extensively, results have been inconsistent. This review analyzes the results of association studies between miRNA SNPs and BC risk from countries around the world. We conclude that: (a) By continent, the largest proportion of studies to date were conducted in Asia (65.0 %) and the smallest proportion in Africa (1.8 %); (b) Association studies have been completed for 67 different SNPs; (c) 146a, 196a2, 499, 27a, and 423 are the most-studied miRNAs; (d) The SNPs rs2910164 (miRNA-146a), rs11614913 (miRNA-196a2), rs3746444 (miRNA-499) and rs6505162 (miRNA-423) were the most widely associated with increased BC risk; (e) The majority of studies had small samples, which may affect the precision and power of the results; and (f) The effect of an SNP on BC risk depends on the ethnicity of the population. This review also discusses potential explanations for controversial findings.
Collapse
Affiliation(s)
- Trinidad Arancibia
- Programa de Genética Humana, Instituto de Ciencia Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, 8380453, Santiago, Chile
| | - Sebastian Morales-Pison
- Programa de Genética Humana, Instituto de Ciencia Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, 8380453, Santiago, Chile
| | - Edio Maldonado
- Programa Biología Celular y Molecular, Facultad de Medicina, Universidad de Chile, 8380453, Santiago, Chile
| | - Lilian Jara
- Programa de Genética Humana, Instituto de Ciencia Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, 8380453, Santiago, Chile.
| |
Collapse
|
2
|
Majumder M, Ugwuagbo KC, Maiti S, Lala PK, Brackstone M. Pri-miR526b and Pri-miR655 Are Potential Blood Biomarkers for Breast Cancer. Cancers (Basel) 2021; 13:cancers13153838. [PMID: 34359739 PMCID: PMC8345356 DOI: 10.3390/cancers13153838] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Accepted: 07/28/2021] [Indexed: 01/05/2023] Open
Abstract
Simple Summary Previously, we reported that the expression of two oncogenic miRNAs, miR526b and miR655, in poorly metastatic breast cancer cells enhances aggressive breast cancer phenotypes. Furthermore, miR526b and miR655 expression in breast tumors is associated with poor patient survival. We recently showed that both miRNAs are major regulators of the tumor microenvironment and can be detected in cell-free tumor cell secretions. Therefore, we wanted to test the biomarker potential of these two miRNAs. Early detection can improve breast cancer patient survival by 98%. Here, we report novel findings that precursors of both miRNAs, pri-miR526b and pri-miR655, are sensitive and robust blood biomarkers to distinguish cancer from benign plasmas. Pri-miR526b proved to be a very sensitive biomarker in detecting breast cancer at an early stage. Hence, pri-miR526b can be used as an early diagnostic biomarker for breast cancer. Abstract We reported that two microRNAs, miR526b and miR655, are oncogenic in breast cancer (BC). Overexpression of these two miRNAs in poorly metastatic BC cells promotes aggressive BC phenotypes in vitro and in vivo. High expression of each miRNA was associated with poor patient survival. In this pilot biomarker study, we report for the first time that miRNA precursor RNAs (pri-miRNAs) are robust and sensitive biomarkers for BC, detectable in both human blood plasma and biopsy tissues. Pri-miRNA detection and quantification do not require a special enrichment procedure, thus reducing specimen quantity. Blood plasma samples from 90 malignant tumor-bearing patients and 20 benign lesion-bearing participants (control) were analyzed for pri-miRNA expression with a quantitative real-time polymerase chain reaction. Results revealed that normalized expressions of plasma pri-miR526b and pri-miR655 are significantly upregulated in malignancy compared to benign plasmas (p = 0.002 and p = 0.03, respectively). Both pri-miRNAs showed more prominent results to distinguish stage I plasmas from benign plasmas (p = 0.001 for pri-miR526b and p = 0.0001 for pri-miR655). We have also validated pri-miRNA expression in independent tumor bank tissues, showing significant upregulation of both pri-miRNAs in BC; thus, pri-miRNAs are robust markers. The diagnostic relevance of pri-miRNAs was computed with the area under the curve (AUC). Pri-miR526b is a sensitive biomarker to distinguish cancer from control plasmas (sensitivity of 86%; AUC = 71.47%, p = 0.0027) with a positive predictive value of 88.89%; however, pri-miR655 did not show significant sensitivity. Furthermore, pri-miR526b could also significantly distinguish tumors as early as stage I from control (sensitivity of 75%; AUC = 72.71%, p = 0.0037). Therefore, pri-miR526b can be used as an early diagnostic biomarker. The expression of both pri-miRNAs was significantly high in ER-positive and HER2-negative subgroups of BC; hence, these biomarkers might play a role in the management of endocrine therapy designs. Additionally, with a case–control cohort study, we identified that high expression of pri-miR526b in the blood is also a risk factor associated with breast cancer (OR = 4.3, CI = 1.39–13.34, p = 0.01). Pri-miRNAs could be considered novel breast cancer blood biomarkers.
Collapse
Affiliation(s)
- Mousumi Majumder
- Department of Biology, Brandon University, Brandon, MB R7A 6A9, Canada; (K.C.U.); (S.M.)
- Correspondence:
| | | | - Sujit Maiti
- Department of Biology, Brandon University, Brandon, MB R7A 6A9, Canada; (K.C.U.); (S.M.)
| | - Peeyush K Lala
- Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON N6A 5W9, Canada; (P.K.L.); (M.B.)
- Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON N6A 3K7, Canada
| | - Muriel Brackstone
- Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON N6A 5W9, Canada; (P.K.L.); (M.B.)
- Lawson Research Institute, London, ON N6C 2R5, Canada
| |
Collapse
|
3
|
Brincas HM, Augusto DG, Mathias C, Cavalli IJ, Lima RSD, Kuroda F, Urban CDA, Gradia DF, de Oliveira J, de Almeida RC, Ribeiro EMDSF. A genetic variant in microRNA-146a is associated with sporadic breast cancer in a Southern Brazilian Population. Genet Mol Biol 2020; 42:e20190278. [PMID: 32142098 PMCID: PMC7198002 DOI: 10.1590/1678-4685-gmb-2019-0278] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2019] [Accepted: 11/21/2019] [Indexed: 01/20/2023] Open
Abstract
MicroRNAs (miRNAs) play an essential role in gene expression and affect the
development of tumours, including breast cancer (BC). Polymorphisms in miRNA
genes can affect the interaction of miRNAs with their target messenger RNA by
interfering, creating or disrupting target sites. The single nucleotide
polymorphism (SNP) rs2910164, located in the seed region of
miR146a, was shown to be associated with BC among different populations. In the
present study, we investigated whether rs2910164 is associated
with BC in 326 patients and 411 controls from a Brazilian population of
predominantly European ancestry. The presence of the allele
rs2910164*C was associated with an increased risk of BC
(OR=1.4, 95% CI=1.03-1.85, p = 0.03). We also analysed publicly
available RNA-seq data to evaluate if miR146a is differentially expressed in
different subtypes of BC. Genotyping was performed by polymerase chain reaction
with sequence-specific primers (PCR-SSP). By leveraging public data from TCGA
database, we analysed 461 patients and found that miR146a is significantly more
expressed in BC than in non-tumor tissue (1.47 fold, p = 0.02)
and is expressed to a greater degree in aggressive BC subtypes.
Collapse
Affiliation(s)
| | - Danillo G Augusto
- Hospital Nossa Senhora das Graças, Centro de Doenças da Mama, Curitiba, Paraná, Brazil
| | - Carolina Mathias
- Universidade Federal do Paraná, Departamento de Genética, Curitiba, Paraná, Brazil
| | - Iglenir João Cavalli
- Universidade Federal do Paraná, Departamento de Genética, Curitiba, Paraná, Brazil
| | | | - Flávia Kuroda
- Hospital Nossa Senhora das Graças, Centro de Doenças da Mama, Curitiba, Paraná, Brazil
| | | | - Daniela Fiori Gradia
- Universidade Federal do Paraná, Departamento de Genética, Curitiba, Paraná, Brazil
| | | | | | | |
Collapse
|
4
|
Al-Lawati NA, Shenoy SM, Al-Bahrani BJ, Al-Lawati JA. Increasing Thyroid Cancer Incidence in Oman: A Joinpoint Trend Analysis. Oman Med J 2020; 35:e98. [PMID: 32095279 PMCID: PMC7029156 DOI: 10.5001/omj.2020.16] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2019] [Accepted: 07/22/2019] [Indexed: 12/13/2022] Open
Abstract
Objectives We sought to investigate the epidemiology of thyroid cancer and its trends in Oman over a 20-year period. Methods We analyzed all cases of primary thyroid cancer reported to the Oman National Cancer Registry between 1996 and 2015. Age-standardized incidence rates (ASR) were calculated using the World Standard Population. Joinpoint regression was used to assess trends and obtain annual percentage changes (APC) in incidence rates with 95% confidence intervals (95% CI) and p-values at the alpha = 0.050 level. Gender-specific APC was used to project thyroid cancer incidence rates in Oman over the next 20 years. Population attributable fraction was calculated for obesity and current non-smoking. Results A total of 1285 cases of primary thyroid cancer cases were registered in Oman between 1996 and 2015, with a female to male ratio of 4:1. In men, the ASR was 2.0 per 100 000 while in females it was 7.6 per 100 000 (p < 0.010). Over 80.0% of thyroid tumors were of a papillary type and 19.0% follicular type. Statistically significant trends for thyroid cancer were detected in women from 2008–2015 (APC = 14.3%, 95% CI: 8.0–20.9, p < 0.010) and among both genders (APC = 16.7%, 95% CI: 4.9–29.9, p < 0.010). If current trends continue, thyroid cancer incidence will increase to 3.1, 16.6, and 11.8 per 100 000 by 2040 in men, women, and both genders, respectively. Nearly 10.0% of thyroid cancer can be prevented by controlling obesity in the Omani population. Conclusions Oman has had moderate incidence rates of thyroid cancer with an increasing trend among women. Since projections estimate that the rates of this disease will double in women over the next 20 years, health authorities should consider providing sufficient resources to manage this condition and establish prevention programs that address obesity as part of the strategy for the prevention and control of noncommunicable diseases.
Collapse
Affiliation(s)
- Najla A Al-Lawati
- Department of Non-communicable Diseases Control, Directorate General of Primary Health Care, Ministry of Health, Muscat, Oman
| | - Sarooj M Shenoy
- Department of Non-communicable Diseases Control, Directorate General of Primary Health Care, Ministry of Health, Muscat, Oman
| | - Bassim J Al-Bahrani
- Department of Medical Oncology, National Oncology Centre, Royal Hospital, Muscat, Oman
| | - Jawad A Al-Lawati
- Directorate General of Primary Health Care, Ministry of Health, Muscat, Oman
| |
Collapse
|
5
|
Bastami M, Choupani J, Saadatian Z, Zununi Vahed S, Ouladsahebmadarek E, Mansoori Y, Daraei A, Samadi Kafil H, Yousefi B, Mahdipour M, Masotti A, Nariman-Saleh-Fam Z. Evidences from a Systematic Review and Meta-Analysis Unveil the Role of MiRNA Polymorphisms in the Predisposition to Female Neoplasms. Int J Mol Sci 2019; 20:ijms20205088. [PMID: 31615040 PMCID: PMC6834313 DOI: 10.3390/ijms20205088] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2019] [Revised: 09/24/2019] [Accepted: 10/10/2019] [Indexed: 12/24/2022] Open
Abstract
Breast (BCa) and gynecological (GCa) cancers constitute a group of female neoplasms that has a worldwide significant contribution to cancer morbidity and mortality. Evidence suggests that polymorphisms influencing miRNA function can provide useful information towards predicting the risk of female neoplasms. Inconsistent findings in the literature should be detected and resolved to facilitate the genetic screening of miRNA polymorphisms, even during childhood or adolescence, and their use as predictors of future malignancies. This study represents a comprehensive systematic review and meta-analysis of the association between miRNA polymorphisms and the risk of female neoplasms. Meta-analysis was performed by pooling odds-ratios (ORs) and generalized ORs while using a random-effects model for 15 miRNA polymorphisms. The results suggest that miR-146a rs2910164 is implicated in the susceptibility to GCa. Moreover, miR-196a2 rs11614913-T had a moderate protective effect against female neoplasms, especially GCa, in Asians but not in Caucasians. MiR-27a rs895819-G might pose a protective effect against BCa among Caucasians. MiR-499 rs3746444-C may slightly increase the risk of female neoplasms, especially BCa. MiR-124 rs531564-G may be associated with a lower risk of female neoplasms. The current evidences do not support the association of the remaining polymorphisms and the risk of female neoplasms.
Collapse
Affiliation(s)
- Milad Bastami
- Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5166614756, Iran.
| | - Jalal Choupani
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5166614756, Iran.
| | - Zahra Saadatian
- Department of Basic Sciences, Faculty of Medicine, Gonabad University of Medical Sciences, Gonabad 9691793718, Iran.
| | - Sepideh Zununi Vahed
- Kidney Research Center, Tabriz University of Medical Sciences, Tabriz 5166614756, Iran.
| | - Elaheh Ouladsahebmadarek
- Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz 5138663134, Iran.
| | - Yasser Mansoori
- Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa 7461686688, Iran.
| | - Abdolreza Daraei
- Department of Genetics, Faculty of Medicine, Babol University of Medical Sciences, Babol 4617647745, Iran.
| | - Hossein Samadi Kafil
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5166614756, Iran.
| | - Bahman Yousefi
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 5165665811, Iran.
| | - Mahdi Mahdipour
- Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz 5166614756, Iran.
- Department of Reproductive Biology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran.
| | - Andrea Masotti
- Research Laboratories, Bambino Gesù Children's Hospital-IRCCS, Rome 00146, Italy.
| | - Ziba Nariman-Saleh-Fam
- Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz 5138663134, Iran.
| |
Collapse
|